Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice

Authors: Qingshan Wang, Eun-Joo Shin, Xuan-Khanh Thi Nguyen, Quan Li, Jae-Hyung Bach, Guoying Bing, Won-Ki Kim, Hyoung-Chun Kim, Jau-Shyong Hong

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Background

The striato-nigral projecting pathway contains the highest concentrations of dynorphin in the brain. The functional role of this opioid peptide in the regulation of mesencephalic dopaminergic (DAergic) neurons is not clear. We reported previously that exogenous dynorphin exerts potent neuroprotective effects against inflammation-induced dopaminergic neurodegeneration in vitro. The present study was performed to investigate whether endogenous dynorphin has neuroprotective roles in vivo.

Methods

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine (MA), two commonly used neurotoxins in rodent models of Parkinson’s disease, were administered to wild-type (Dyn+/+) and prodynorphin-deficient mice (Dyn−/−). We examined dopaminergic neurotoxicity by using an automated video tracking system, HPLC, immunocytochemistry, and reverse transcription and polymerase chain reaction (RT-PCR).

Results

Treatment with MPTP resulted in behavioral impairments in both strains. However, these impairments were more pronounced in Dyn-l- than in Dyn+/+. Dyn−/− showed more severe MPTP-induced dopaminergic neuronal loss in the substantia nigra and striatum than Dyn+/+. Similarly, the levels of dopamine and its metabolites in the striatum were depleted to a greater extent in Dyn−/− than in Dyn+/+. Additional mechanistic studies revealed that MPTP treatment caused a higher degree of microglial activation and M1 phenotype differentiation in Dyn−/− than in Dyn+/+. Consistent with these observations, prodynorphin deficiency also exacerbated neurotoxic effects induced by MA, although this effect was less pronounced than that of MPTP.

Conclusions

The in vivo results presented here extend our previous in vitro findings and further indicate that endogenous dynorphin plays a critical role in protecting dopaminergic neurons through its anti-inflammatory effects.
Appendix
Available only for authorised users
Literature
1.
Graybiel AM: The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 2005, 15:638–644.CrossRefPubMed
2.
Carey AN, Lyons AM, Shay CF, Dunton O, McLaughlin JP: Endogenous kappa opioid activation mediates stress-induced deficits in learning and memory. J Neurosci 2009, 29:4293–4300.CrossRefPubMed
3.
Reid MS, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, Ungerstedt U: Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res 1990, 82:293–303.CrossRefPubMed
4.
Steiner H, Gerfen CR: Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 1998, 123:60–76.CrossRefPubMed
5.
You ZB, Herrera-Marschitz M, Terenius L: Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Ther 1999, 290:1307–1315.PubMed
6.
Gerfen CR, McGinty JF, Young WS: Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991, 11:1016–1031.PubMed
7.
8.
Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP: Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chorea. Neuroscience 1988, 25:419–438.CrossRefPubMed
9.
Carta A, Fenu S, Morelli M: Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease. Neurol Sci 2001, 22:59–60.CrossRefPubMed
10.
Bezard E, Brotchie JM, Gross CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001, 2:577–588.CrossRefPubMed
11.
Klintenberg R, Svenningsson P, Gunne L, Andren PE: Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. J Neural Transm 2002, 109:1295–1307.CrossRefPubMed
12.
Liu B, Qin L, Yang SN, Wilson BC, Liu Y, Hong JS: Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. J Pharmacol Exp Ther 2001, 298:1133–1141.PubMed
13.
Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, Wilson B, Yang J, Hong JS: Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 2006, 20:251–258.CrossRefPubMed
14.
Qin L, Block ML, Liu Y, Bienstock RJ, Pei Z, Zhang W, Wu X, Wilson B, Burka T, Hong JS: Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J 2005, 19:550–557.CrossRefPubMed
15.
Sharifi N, Diehl N, Yaswen L, Brennan MB, Hochgeschwender U: Generation of dynorphin knockout mice. Brain Res Mol Brain Res 2001, 86:70–75.CrossRefPubMed
16.
Nguyen XV, Liu M, Kim HC, Bing G: Effects of prodynorphin deletion on striatal dopamine in mice during normal aging and in response to MPTP. Exp Neurol 2009, 219:228–238.CrossRefPubMed
17.
Shin EJ, Jang CG, Bing G, Park DH, Oh CH, Koo KH, Oh KW, Yamada K, Nabeshima T, Kim HC: Prodynorphin gene deficiency potentiates nalbuphine-induced behavioral sensitization and withdrawal syndrome in mice. Drug Alcohol Depend 2009, 104:175–184.CrossRefPubMed
18.
Sedelis M, Schwarting RKW, Huston JP: Behavioral phenotypine of the MPTP mouse model of Parkinson’s disease. Behav Brain Res 2001, 125:109–122.CrossRefPubMed
19.
Schwarting RKW, Sedelis M, Hofele K, Auburger GW, Huston JP: Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkonson’s disease. Neurotox Res 1999, 1:41–56.CrossRefPubMed
20.
Chou J, Luo Y, Kuo CC, Powers K, Shen H, Harvey BK, Hoffer BJ, Wang Y: Bone morphogenetic protein-7 reduces toxicity induced by high doses of methamphetamine in rodents. Neuroscience 2008, 151:92–103.CrossRefPubMed
21.
Nguyen XV, Liu M, Kim HC, Bing G: Effects of prodynorphin deletion on striatal dopamine in mice during normal aging and in response to MPTP. Exp Neurol 2009, 219:228–238.CrossRefPubMed
22.
Qian L, Wu HM, Chen SH, Zhang D, Ali SF, Peterson L, Wilson B, Lu RB, Hong JS, Flood PM: beta2-adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. J Immunol 2011, 186:4443–4454.CrossRefPubMedPubMedCentral
23.
Shin EJ, Duong CX, Nguyen TX, Bing G, Bach JH, Park DH, Nakayama K, Ali SF, Kanthasamy AG, Cadet JL, et al.: PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochem Int 2011, 59:39–50.CrossRefPubMedPubMedCentral
24.
Zhang W, Shin EJ, Wang T, Lee PH, Pang H, Wie MB, Kim WK, Kim SJ, Huang WH, Wang Y, Zhang W, Hong JS, Kim HC: 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage bothin vivoandin vitro. FASEB J 2006, 20:2496–2511.CrossRefPubMed
25.
Nguyen TXK, Bach JH, Pham DT, Shin EJ, Hong JS, Kim HC: Prodynorphin gene depletion exacerbates dopaminergic neurotoxicity induced by MPTP or methamphetamine. In 3rdInternational Drug Abuse Research Society Meeting. Poster 62; 23–26 August 2011. Edited by: Syed F. Ali: International Drug Abuse Research Society, Istanbul, Turkey; 2011:89.
26.
Kim HC, Shin CY, Seo DO, Jhoo JH, Jhoo WK, Kim WK, Shin EJ, Lee YH, Lee PH, Ko KH: New morphinan derivatives with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. Life Sci 2003, 72:1883–1895.CrossRefPubMed
27.
Jung BD, Shin EJ, Nguyen XK, Jin CH, Bach JH, Park SJ, Nah SY, Wie MB, Bing G, Kim HC: Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 2010, 56:229–244.CrossRefPubMed
28.
Kim HC, Jhoo WK, Choi DY, Im DH, Shin EJ, Suh JH, Floyd RA, Bing G: Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res 1999, 851:76–86.CrossRefPubMed
29.
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG: Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29:13435–13444.CrossRefPubMedPubMedCentral
30.
Bing G, Zhang Y, Watanabe Y, McEwen BS, Stone EA: Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 1994, 668:261–265.CrossRefPubMed
31.
Pellegrino D, Cicchetti F, Wang X, Zhu A, Yu M, Saint-Pierre M, Brownell AL: Modulation of dopaminergic and glutamatergic brain function: PET Studies on Parkinsonian rats. J Nucl Med 2007, 48:1147–1153.CrossRefPubMed
32.
Maximova OA, Taffs RE, Pomeroy KL, Piccardo P, Asher DM: Computerized morphometric analysis of pathological prion protein deposition in scrapie-infected hamster brain. J Histochem Cytochem 2006, 54:97–107.CrossRefPubMed
33.
West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991, 231:482–497.CrossRefPubMed
34.
Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM: TNF-alpha knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007, 26:36–46.CrossRefPubMedPubMedCentral
35.
Gundersen HJ, Jensen EB, Kieu K, Nielsen J: The efficiency of systematic sampling in stereology–reconsidered. J Microsc 1999, 193:199–211.CrossRefPubMed
36.
37.
Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA: Rapamycin protects against neuron death inin vitroandin vivomodels of Parkinson’s disease. J Neurosci 2010, 30:1166–1175.CrossRefPubMedPubMedCentral
38.
Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S: Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2001, 98:2837–2842.CrossRefPubMedPubMedCentral
39.
Belin D, Everitt BJ: Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2008, 57:432–441.CrossRefPubMed
40.
Karl T, Pabst R, von Horsten S: Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol 2003, 55:69–83.CrossRefPubMed
41.
Rozas G, Labandeira Garcia JL: Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res 1997, 49:188–199.CrossRef
42.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57–69.CrossRefPubMed
43.
Gao HM, Liu B, Zhang W, Hong JS: Critical role of microglial NADPH oxidase-derived free radicals in thein vitroMPTP model of Parkinson's disease. FASEB J 2003, 17:1954–1956.PubMed
44.
Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS, Hong JS, Block ML: Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 2010, 133:808–821.CrossRefPubMedPubMedCentral
45.
46.
Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR: Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 1997, 282:834–838.PubMed
47.
Vergo S, Johansen JL, Leist M, Lotharius J: Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 2007, 1185:18–32.CrossRefPubMed
48.
Kim HC, Jhoo WK, Shin EJ, Bing G: Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Research 2000, 862:247–252.CrossRefPubMed
49.
Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED: Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Research 1996, 738:172–175.CrossRefPubMed
50.
Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF: Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Research 1996, 742:80–88.CrossRefPubMed
51.
Dauer W, Przedborski S: Parkinson’s disease: mechanisms and models. Neuron. 2003, 39:889–909.PubMed
52.
Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Holson RR: Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994, 268:1571–1580.PubMed
53.
Albers DS, Sonsalla PK: Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 1995, 275:1104–1114.PubMed
54.
Ricaurte GA, Fuller RW, Perry KW, Seiden LS, Schuster CR: Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of D-methamphetamine and D-amphetamine. Neuropharmacology 1983, 22:1165–1169.CrossRefPubMed
55.
Wagner GC, Lucot JB, Schuster CR, Seiden LS: α-Methyltyrosine attenuates and reserpine increases methamphetamine-induced neuronal changes. Brain Research 1983, 270:285–288.CrossRefPubMed
56.
Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG: Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 1999, 19:2424–2431.PubMed
57.
Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hong JS: Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002, 83:973–983.CrossRefPubMed
58.
Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 2011, 31:1081–1092.CrossRefPubMedPubMedCentral
59.
Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B, Miller DS, Chen B, McGeer PL, Hong JS, Zhang J: Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007, 55:1178–1188.CrossRefPubMed
60.
Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, Hong JS: Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 2008, 181:7194–7204.CrossRefPubMedPubMedCentral
61.
LaVoie MJ, Card JP, Hastings TG: Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 2004, 187:47–57.CrossRefPubMed
62.
McGeer PL, Schwab C, Parent A, Doudet D: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599–604.CrossRefPubMed
63.
Kong LY, McMillian MK, Hudson PM, Jin L, Hong JS: Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Pharmacol Exp Ther 1997, 280:61–66.PubMed
Metadata
Title
Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice
Authors
Qingshan Wang
Eun-Joo Shin
Xuan-Khanh Thi Nguyen
Quan Li
Jae-Hyung Bach
Guoying Bing
Won-Ki Kim
Hyoung-Chun Kim
Jau-Shyong Hong
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-124

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue

Research

IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci

Research

Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse

Research

CC chemokine ligand 2 upregulates the current density and expression of TRPV1 channels and Nav1.8 sodium channels in dorsal root ganglion neurons

Research

Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity

Research

Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results

Research

Menopause leads to elevated expression of macrophage-associated genes in the aging frontal cortex: rat and human studies identify strikingly similar changes